131 related articles for article (PubMed ID: 21756414)
1. Differences among formulary submission guidelines: implications for health technology assessment.
Mauskopf J; Walter J; Birt J; Bowman L; Copley-Merriman C; Drummond M
Int J Technol Assess Health Care; 2011 Jul; 27(3):261-70. PubMed ID: 21756414
[TBL] [Abstract][Full Text] [Related]
2. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
3. Health economic guidelines--similarities, differences and some implications.
Hjelmgren J; Berggren F; Andersson F
Value Health; 2001; 4(3):225-50. PubMed ID: 11705185
[TBL] [Abstract][Full Text] [Related]
4. Health technology assessment. The pharmaceutical industry perspective.
Schubert F
Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
[TBL] [Abstract][Full Text] [Related]
5. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
6. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
Langley PC
Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
[TBL] [Abstract][Full Text] [Related]
7. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
8. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluations in European reimbursement submission guidelines: current status and comparisons.
Bracco A; Krol M
Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):579-95. PubMed ID: 24138645
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
11. Meeting the information needs of drug purchasers: the evolution of formulary submission guidelines.
Langley PC
Clin Ther; 1999 Apr; 21(4):768-87; discussion 767. PubMed ID: 10363741
[TBL] [Abstract][Full Text] [Related]
12. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
Anis AH; Gagnon Y
Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of pharmaceuticals: a European perspective.
Drummond M; Rutten F; Brenna A; Pinto CG; Horisberger B; Jönsson B; Le Pen C; Rovira J; von der Schulenburg MG; Sintonen H
Pharmacoeconomics; 1993 Sep; 4(3):173-86. PubMed ID: 10146921
[TBL] [Abstract][Full Text] [Related]
14. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
15. Toward transparency in health technology assessment: a checklist for HTA reports.
Hailey D
Int J Technol Assess Health Care; 2003; 19(1):1-7. PubMed ID: 12701934
[TBL] [Abstract][Full Text] [Related]
16. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
[TBL] [Abstract][Full Text] [Related]
17. EVIDENCE REQUIREMENTS FOR REIMBURSEMENT OF PHARMACEUTICALS ACROSS EUROPE.
Oyebode O; Garrett Z; George E; Cangini A; Muscolo LA; Warren S; Nemeth B; Földesi C; Heislerová M; Gajdošová E
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):59-67. PubMed ID: 26168803
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines.
Betts MB; Milev S; Hoog M; Jung H; Milenković D; Qian Y; Tai MH; Kutikova L; Villa G; Edwards C
Value Health; 2019 Feb; 22(2):210-219. PubMed ID: 30711066
[TBL] [Abstract][Full Text] [Related]
19. International Regulations and Recommendations for Utility Data for Health Technology Assessment.
Rowen D; Azzabi Zouraq I; Chevrou-Severac H; van Hout B
Pharmacoeconomics; 2017 Dec; 35(Suppl 1):11-19. PubMed ID: 29052162
[TBL] [Abstract][Full Text] [Related]
20. Appropriate evidence sources for populating decision analytic models within health technology assessment (HTA): a systematic review of HTA manuals and health economic guidelines.
Zechmeister-Koss I; Schnell-Inderst P; Zauner G
Med Decis Making; 2014 Apr; 34(3):288-99. PubMed ID: 24135150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
